RANCHO SANTA MARGARITA, Calif., Dec. 16, 2002 (PRIMEZONE) -- BioCurex Inc. (OTCBB:BOCX) is pleased to announce that it has completed a licensing agreement with BioKinetix to use BioCurex's RECAF technology. The license will allow BioKinetix to use its InNexus Super Antibody platform technology to create therapeutic antibodies. Combining RECAF antibodies with Super Antibody technology could give BioKinetix the potential to create both highly potent therapeutic antibodies, as well as vaccines to immunize against the RECAF receptor.
Dr. Moro, President of BioCurex Inc., stated, "We are very pleased to have further recognition of the value of our RECAF technology and our expertise. We are continuing to work with scientists at various corporations to advance our company, as well as to distribute our present products. Each opportunity allows us to expand our network of scientific groups working with us to achieve our goal of helping patients in the diagnosis and management of cancer."
RJV Network, Inc. (OTCBB:RJVN), a Nevada corporation, is in the process of acquiring BioKinetix Research Inc.
BioCurex, Inc. is a biotechnology company that is developing products based on patented/proprietary technology in the areas of cancer diagnosis, tumor imaging ad therapeutics. The technology identifies a cancer marker known as RECAF(tm), which is found on malignant cells from a variety of cancer types but absent in most normal or benign cells. Detailed information about BioCurex may be obtained from their website at http://www.biocurex.com .
Statements in this press release, which are not historical facts, are "forward-looking statements" within the meaning given to that term in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements by subject to the safe harbors created thereby. Since these statements involve risks and uncertainties and are subject to change at any time, the Company's actual results could differ materially from expected results.